Document:

Form of Severance Agreement

 Exhibit 10.1 
 FORM OF 
 SEVERANCE AGREEMENT 

THIS SEVERANCE AGREEMENT (the “Agreement”), dated as of
                    , is made and entered by and between Harman International Industries, Incorporated (“Harman” or, including any
successor thereto, the “Company”), a Delaware corporation, and                     (the “Executive”). 

WHEREAS, the Executive is a senior executive of Harman and is expected to make major contributions to the Company’s short and
long-term profitability, growth and financial strength; 
 WHEREAS, Harman recognizes that: (a) top-quality executives may
seek more secure career opportunities if a Change in Control, as defined below, occurs in the future; and (b) the Company may encounter difficulties in recruiting qualified senior executives unless it offers an employment security arrangement,
applicable in Change in Control situations; 
 WHEREAS, Harman desires to assure itself of both present and future continuity of
management and desires to establish certain minimum severance benefits for certain of its senior executives, including the Executive, applicable in the event of a Change in Control; 

WHEREAS, Harman wishes to ensure that its senior executives are not practically disabled from discharging their duties in respect of a
proposed or actual transaction involving a Change in Control; and 
 WHEREAS, Harman desires to provide additional inducement
for the Executive to continue to remain in the Company’s employ. 
 NOW, THEREFORE, Harman and the Executive agree as
follows: 
 1. Certain Defined Terms. In addition to terms defined elsewhere in this Agreement, the following terms have
the following meanings: 
 (a) “Base Pay” means the Executive’s annual base salary rate as in effect from
time to time; 
 (b) “Board” means Harman’s Board of Directors; 

(c) “Cause” means that, prior to any termination pursuant to Section 3(b), the Executive shall have: 

(i) been convicted of a criminal violation involving fraud, embezzlement or theft in connection with his duties or in the
course of his employment with the Company or any Subsidiary; 
 (ii) committed intentional wrongful damage to
property of Harman or any Harman subsidiary; 

 (iii) committed intentional wrongful disclosure of secret processes or
confidential information of Harman or any Subsidiary; or 
 (iv) committed intentional wrongful engagement in any
Competitive Activity; 
 and any such act shall have been demonstrably and materially harmful to Harman. For purposes of this
Agreement, no act or failure to act on the part of the Executive shall be deemed “intentional” if it was due primarily to an error in judgment or negligence, but shall be deemed “intentional” only if done or omitted to be done by
the Executive not in good faith and without reasonable belief that the Executive’s action or omission was in the best interest of Harman. Notwithstanding the foregoing, the Executive shall not be deemed to have been terminated for
“Cause” hereunder unless and until there shall have been delivered to the Executive a copy of a resolution duly adopted by the affirmative vote of a majority of the Committee then in office at a meeting of the Committee called and held for
such purpose, after reasonable notice to the Executive and an opportunity for the Executive, together with the Executive’s counsel (if the Executive chooses to have counsel present at such meeting), to be heard before the Committee, finding
that, in the good faith opinion of the Committee, the Executive had committed an act constituting “Cause” as defined in this Agreement and specifying the particulars thereof in detail. Nothing in this Agreement will limit the right of the
Executive or his beneficiaries to contest the validity or propriety of any such determination; 
 (d) “Change in
Control” means the occurrence during the Term of any of the following events: 
 (i) The acquisition by
any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act) (a “Person”) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 25% or more
of the combined voting power of the then outstanding Voting Stock of the Company; provided, however, that for purposes of this Section 1(d)(i), the following acquisitions shall not constitute a Change in Control: (A) any issuance of Voting
Stock of the Company directly from the Company that is approved by the Incumbent Board (as defined in Section 1(d)(ii), below), (B) any acquisition by the Company or a Subsidiary of Voting Stock of the Company, (C) any acquisition of
Voting Stock of the Company by any employee benefit plan (or related trust) sponsored or maintained by the Company or any Subsidiary, or (D) any acquisition of Voting Stock of the Company by any Person pursuant to a Business Combination (as
defined in Section 1(d)(iii) below) that complies with clauses (A), (B) and (C) of Section 1(d)(iii), below; or 
 (ii) individuals who, as of the date hereof, constitute the Board (the “Incumbent Board”) cease for any reason to constitute at least a majority of the Board; provided,
however, that any individual becoming a Director after the date hereof whose election, or nomination for election by the Company’s shareholders, was approved by a vote of at least two-thirds of the Directors then comprising the Incumbent
Board (either by a specific vote or by approval of the proxy statement of the Company in which such person is named as a nominee for director, without objection to such nomination) shall be 

  
 2 

 
deemed to have been a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election
contest (within the meaning of Rule 14a-11 of the Exchange Act) with respect to the election or removal of Directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board; or

 (iii) consummation of a reorganization, merger or consolidation, a sale or other disposition of all or
substantially all of the assets of the Company, or other transaction (each, a “Business Combination”), unless, in each case, immediately following such Business Combination, (A) all or substantially all of the individuals and
entities who were the beneficial owners of Voting Stock of the Company immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of the combined voting power of the then outstanding shares of Voting Stock
of the entity resulting from such Business Combination (including, without limitation, an entity which as a result of such transaction owns the Company or all or substantially all of the Company’s assets either directly or through one or more
subsidiaries), (B) no Person (other than the Company, such entity resulting from such Business Combination, or any employee benefit plan (or related trust) sponsored or maintained by the Company, any Subsidiary or such entity resulting from
such Business Combination) beneficially owns, directly or indirectly, 25% or more of the combined voting power of the then outstanding shares of Voting Stock of the entity resulting from such Business Combination, and (C) at least a majority of
the members of the Board of Directors of the entity resulting from such Business Combination were members of the Incumbent Board at the time of the execution of the initial agreement or of the action of the Board providing for such Business
Combination; or 
 (iv) approval by the shareholders of the Company of a complete liquidation or dissolution of
the Company, except pursuant to a Business Combination that complies with clauses (A), (B) and (C) of Section 1(d)(iii). 
 (e) “Committee” means the Compensation and Option Committee of the Board or such similar committee of the Board comprised of non-officer directors and responsible for executive
compensation matters of the Company generally; 
 (f) “Competitive Activity” means the Executive’s
participation, without the Company’s written consent, in the management of any business enterprise if such enterprise engages in substantial and direct competition with the Company or a Subsidiary and the enterprise’s sales of any product
or service under the Executive’s supervision competitive with any product or service of the Company or a Subsidiary amounted to 10% of the enterprise’s net sales for its most recently completed fiscal year and if the Company’s and its
Subsidiary’s net sales of said product or service amounted to 10% of the Company’s net sales for its most recently completed fiscal year. “Competitive Activity” will not include (i) the mere ownership of securities in any
such enterprise and the exercise of rights appurtenant thereto or (ii) participation in the management of any such enterprise other than in connection with the competitive operations of such enterprise; 

  
 3 

 (g) “Employee Benefits” means the perquisites, benefits and service credit
for benefits as provided under any and all employee retirement income and welfare benefit policies, plans, programs or arrangements in which Executive is entitled to participate, including without limitation any stock option, performance share,
performance unit, stock purchase, stock appreciation, savings, pension, supplemental executive retirement, or other retirement income or welfare benefit, deferred compensation, incentive compensation, group or other life, health, medical/hospital or
other insurance (whether funded by actual insurance or self-insured by the Company or a Subsidiary), disability, salary continuation, expense reimbursement and other employee benefit policies, plans, programs or arrangements that may now exist or
any equivalent successor policies, plans, programs or arrangements that may be adopted by the Company or a Subsidiary, providing perquisites, benefits and service credit for benefits at least as great in the aggregate as are payable thereunder prior
to a Change in Control; 
 (h) “Exchange Act” means the Securities Exchange Act of 1934, as amended from time
to time; 
 (i) “Incentive Pay” means an annual bonus, incentive or other payment of compensation, in addition
to Base Pay, made or to be made in regard to services rendered in any year or other period pursuant to any bonus, incentive, profit-sharing, performance, discretionary pay or similar agreement, policy, plan, program or arrangement (whether or not
funded) of the Company or a Subsidiary, or any successor thereto; 
 (j) “Retirement Plans” means the
retirement income, supplemental executive retirement, excess benefits and retiree medical, life and similar benefit plans providing retirement perquisites, benefits and service credit for benefits at least as great in the aggregate as are payable
thereunder prior to a Change in Control; 
 (k) “Severance Period” means the period of time commencing six
months prior to the date of the first occurrence of a Change in Control and continuing until the earlier of (i) the second anniversary of the occurrence of the Change in Control, or (ii) the Executive’s death; provided,
however, that commencing on each anniversary of the Change in Control, the Severance Period will automatically be extended for an additional year unless, not later than 90 calendar days before the anniversary date, either the Company or the
Executive shall have given written notice to the other that the Severance Period is not to be so extended; 
 (l)
“Subsidiary” means an entity in which the Company, directly or indirectly, beneficially owns 50% or more of the outstanding Voting Stock; 
 (m) “Term” means the period commencing as of the date hereof and expiring as of the later of (i) the close of business on December 31, 2015, or (ii) the expiration of the
Severance Period. However, commencing on January 1, 2016 and each January 1 thereafter, the term of this Agreement will automatically be extended for an additional year unless, not later than September 30 of the immediately preceding
year, the Company or the Executive shall have given notice that it or the Executive, as the case may be, does not wish to have the Term extended. Furthermore, if prior to the date which is six months prior to a Change in Control, the Executive
ceases for any reason to be an officer of the Company or any Subsidiary, thereupon without further action the Term shall be deemed to have expired and this Agreement will 

  
 4 

 
immediately terminate and be of no further effect. For purposes of this Section, the Executive shall not be deemed to have ceased to be an officer of the Company and any Subsidiary by reason of
the transfer of Executive’s employment between the Company and any Subsidiary, or among any Subsidiaries; 
 (n)
“Termination Date” means the date on which the Executive’s employment is terminated (the effective date of which shall be the date of termination, or such other date that may be specified by the Executive if the termination is
pursuant to Section 3(b)); provided, however, that if the Termination Date precedes the Change in Control, then any additional payments and benefits that are due upon a Change in Control and that are deferred compensation within
the meaning of Section 409A shall be subject to the Section 409A Delay, as defined below, and payable upon the Change in Control; and 
 (o) “Voting Stock” means securities entitled to vote generally in the election of directors. 
 2. Operation of Agreement. This Agreement will be effective and binding immediately upon its execution, but anything in this Agreement to the contrary notwithstanding, this Agreement will not be
operative unless and until the date which is six months prior to a Change in Control. If a Change in Control occurs at any time during the Term, this Agreement shall become operative immediately and retroactively, including without limitation,
notwithstanding that the Term may have since expired. 
 3. Termination Following a Change in Control. (a) In the
event of the occurrence of a Change in Control, the Executive’s employment may be terminated by the Company or a Subsidiary during the Severance Period and the Executive shall be entitled to the benefits provided by Section 4 as a result
thereof or of any termination within six months prior to a Change in Control unless such termination is the result of the occurrence of one or more of the following events: 

(i) The Executive’s death; 
 (ii) The Executive becoming permanently disabled within the meaning of, and begins actually receiving disability benefits pursuant to, the long-term disability plan in effect for, or applicable to,
Executive immediately prior to the Change in Control; or 
 (iii) Cause. 

If, during the Severance Period, the Executive’s employment is terminated by the Company or any Subsidiary other than pursuant to
Section 3(a)(i), 3(a)(ii) or 3(a)(iii), the Executive will be entitled to the benefits provided by Section 4 hereof. 

(b) In the event of the occurrence of a Change in Control, the Executive may terminate employment with the Company and any Subsidiary
during the Severance Period with the right to severance compensation as provided in Section 4 upon the occurrence of one or more of the following events (regardless of whether any other reason, other than Cause, for such termination exists or
has occurred, including without limitation other employment) and shall also 

  
 5 

 
have such severance compensation in the event he had terminated employment upon the occurrence of one or more of the following events within six months prior to the Change in Control: 

(i) Failure to elect or reelect or otherwise to maintain the Executive in the office or the position, or a substantially
equivalent office or position, of or with the Company and/or a Subsidiary (or any successor thereto by operation of law or otherwise), as the case may be, which the Executive held immediately prior to a Change in Control, or the removal of the
Executive as a Director of the Company and/or a Subsidiary (or any successor thereto) if the Executive shall have been a Director of the Company and/or a Subsidiary immediately prior to the Change in Control; 

(ii) (A) A significant adverse change in the nature or scope of the authorities, powers, functions, responsibilities
or duties attached to the position with the Company and any Subsidiary which the Executive held immediately prior to the Change in Control, (B) a reduction in the aggregate of the Executive’s Base Pay and Incentive Pay received from the
Company and any Subsidiary, or (C) the termination or denial of the Executive’s rights to Employee Benefits or a reduction in the scope or value thereof, any of which is not remedied by the Company within 10 calendar days after receipt by
the Company of written notice from the Executive of such change, reduction or termination, as the case may be; 

(iii) A determination by the Executive (which determination will be conclusive and binding upon the parties to this
Agreement, provided that the determination has been made in good faith and in all events will be presumed to have been made in good faith unless otherwise shown by the Company by clear and convincing evidence) that a change in circumstances has
occurred following a Change in Control, including, without limitation, a change in the scope of the business or other activities for which the Executive was responsible immediately prior to the Change in Control, which has rendered the Executive
substantially unable to carry out, has substantially hindered Executive’s performance of, or has caused Executive to suffer a substantial reduction in, any of the authorities, powers, functions, responsibilities or duties attached to the
position held by the Executive immediately prior to the Change in Control, which situation is not remedied within 10 calendar days after the Company receives written notice from the Executive of such determination; 

(iv) The liquidation, dissolution, merger, consolidation or reorganization of the Company or transfer of all or
substantially all of its business and/or assets, unless the successor or successors (by liquidation, merger, consolidation, reorganization, transfer or otherwise) to which all or substantially all of its business and/or assets have been transferred
(by operation of law or otherwise) assumed all duties and obligations of the Company under this Agreement pursuant to Section 11(a); 
 (v) The Company relocates its principal executive offices (if such offices are the principal location of Executive’s work), or requires the Executive to have his principal location of work changed,
to any location that, in either case, is in excess of 50 miles from the principal executive office’s location immediately prior to the Change 

  
 6 

 
in Control, or requires the Executive to travel away from his office in the course of discharging his responsibilities or duties at least 20% more (in terms of aggregate days in any calendar year
or in any calendar quarter when annualized for purposes of comparison to any prior year) than was required of Executive in any of the three full years immediately prior to the Change in Control without, in either case, his prior written consent; or

 (vi) Without limiting the generality or effect of the foregoing, any material breach of this Agreement by the
Company or any successor thereto which is not remedied by the Company within 10 calendar days after receipt by the Company of written notice from the Executive of such breach. 
 (c) A termination by the Company pursuant to Section 3(a) or by the Executive pursuant to Section 3(b) will not affect any rights that the Executive may have pursuant to any agreement, policy,
plan, program or arrangement of the Company or any Subsidiary providing Employee Benefits, which rights shall be governed by the terms thereof; provided that the Executive shall not be entitled to a severance payment or benefit under any other
agreement with the Company, including, without limitation, any employment agreement, if the Executive is entitled to a comparable payment or benefit hereunder. 
 4. Severance Compensation. (a) If the Company or Subsidiary terminates the Executive’s employment during the Severance Period other than pursuant to Section 3(a)(i), 3(a)(ii) or
3(a)(iii), or if the Executive terminates his employment pursuant to Section 3(b), the Company will pay to the Executive, subject to Section 18 hereof as to the Section 409A Delay, the amount described in Paragraph (1) of Annex A
within five business days after the Termination Date and will continue to provide to the Executive the benefits described in Paragraphs (2) and (3) of Annex A for the periods described therein; provided, however, that no
payment that would otherwise be made and no benefit that would otherwise be provided upon a termination of employment that is deferred compensation for purposes of Section 409A shall be made or provided, as the case may be, unless and until
such termination of employment also constitutes a separation from service (within the meaning of Section 409A). 
 (b)
Without limiting the rights of the Executive at law or in equity, if the Company fails to make any payment or provide any benefit required to be made or provided under this Agreement on a timely basis, the Company will pay interest on the amount or
value thereof at an annualized rate of interest equal to the so-called composite “prime rate” as quoted from time to time during the relevant period in The Wall Street Journal , plus 2%. Such interest will be payable as it accrues
on demand. Any change in such prime rate will be effective on and as of the date of such change. 
 (c) Notwithstanding any
provision of this Agreement to the contrary, the parties’ respective rights and obligations under this Section 4 and under Sections 5, 7 and 8 will survive any termination or expiration of this Agreement or the termination of the
Executive’s employment following a Change in Control for any reason whatsoever. 
 5. Limitation on Payments and
Benefits. Notwithstanding any provision of this Agreement to the contrary, if any amount or benefit to be paid or provided under this 

  
 7 

 
Agreement would be an “excess parachute payment,” within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (“Code”), or any successor
provision thereto, but for the application of this sentence, then the payments and benefits identified in the last sentence of this Section 5 to be paid or provided under this Agreement will be reduced to the minimum extent necessary (but in no
event to less than zero) so that no portion of any such payment or benefit, as so reduced, constitutes an excess parachute payment; provided, however, that no such reduction shall be made if it is not thereby possible to eliminate all
excess parachute payments under this Agreement; and provided, further, that the foregoing reduction will be made only if and to the extent that such reduction would result in an increase in the aggregate payment and benefits to be
provided, determined on an after-tax basis (taking into account the excise tax imposed pursuant to Section 4999 of the Code, or any successor provision thereto, any tax imposed by any comparable provision of state law, and any applicable
federal, state and local income and employment taxes). Whether requested by the Executive or the Company, the determination of whether any reduction in such payments or benefits to be provided under this Agreement or otherwise is required pursuant
to the preceding sentence will be made at the expense of the Company by the Company’s independent accountants. The fact that the Executive’s right to payments or benefits may be reduced by reason of the limitations contained in this
Section 5 will not of itself limit or otherwise affect any other rights of the Executive other than pursuant to this Agreement. In the event that any payment or benefit intended to be provided under this Agreement or otherwise is required to be
reduced pursuant to this Section 5, the Company will reduce the Executive’s payment and/or benefits, to the extent required, in the following order: (i) the lump sum payment described in Paragraph (1) of Annex A; (ii) the
lump sum payment described in Paragraph (3) of Annex A; and (iii) the benefits described in Paragraph (2) of Annex A. 
 6. No Mitigation Obligation. The Company hereby acknowledges that it will be difficult and may be impossible for the Executive to find reasonably comparable employment following the Termination
Date and that the non-competition covenant contained in Section 8 will further limit the employment opportunities for the Executive. In addition, the Company acknowledges that its severance pay plans applicable in general to its salaried
employees do not provide for mitigation, offset or reduction of any severance payment received thereunder. Accordingly, the payment of the severance compensation by the Company to the Executive in accordance with the terms of this Agreement is
hereby acknowledged by the Company to be reasonable, and the Executive will not be required to mitigate the amount of any payment provided for in this Agreement by seeking other employment or otherwise, nor will any profits, income, earnings or
other benefits from any source whatsoever create any mitigation, offset, reduction or any other obligation on the part of the Executive under this Agreement or otherwise. 
 7. Legal Fees and Expenses. (a) The Executive shall not be required to incur legal fees and the related expenses associated with the interpretation, enforcement or defense of Executive’s
rights under this Agreement by litigation or otherwise because such costs substantially would detract from the Executive’s benefits under this Agreement. Accordingly, if it should appear to the Executive that the Company has failed to comply
with any of its obligations under this Agreement or in the event that the Company or any other person takes or threatens to take any action to declare this Agreement void or unenforceable, or institutes any litigation or other action or proceeding
designed to deny, or to recover from, the Executive the benefits provided or intended to be provided to the Executive hereunder, the Company 

  
 8 

 
irrevocably authorizes the Executive from time to time to retain counsel of Executive’s choice, at the expense of the Company as hereafter provided, to advise and represent the Executive in
connection with any such interpretation, enforcement or defense, including without limitation the initiation or defense of any litigation or other legal action, whether by or against the Company or any Director, officer, stockholder or other person
affiliated with the Company, in any jurisdiction. Notwithstanding any existing or prior attorney-client relationship between the Company and such counsel, the Company irrevocably consents to the Executive’s entering into an attorney-client
relationship with such counsel, and in that connection the Company and the Executive agree that a confidential relationship shall exist between the Executive and such counsel. Without respect to whether the Executive prevails, in whole or in part,
in connection with any of the foregoing, the Company will pay and be solely financially responsible for any and all attorneys’ and related fees and expenses incurred by the Executive in connection with any of the foregoing. However, if the
Executive brings an action in bad faith, or with no colorable claim of success, the Company shall not pay for any of Executive’s attorneys’ fees or related expenses. 
 (b) Without limiting the obligations of the Company under Section 7(a) of this Agreement, in the event a Change in Control occurs, the performance of the Company’s obligations under this
Section 7 shall be secured by amounts deposited or to be deposited in trust pursuant to certain trust agreements to which the Company shall be a party, which amounts deposited shall in the aggregate be not less than $1,000,000, providing that
the fees and expenses of counsel selected from time to time by the Executive pursuant to Section 7(a) shall be paid, or reimbursed to the Executive if paid by the Executive, either in accordance with the terms of such trust agreements, or, if
not so provided, on a regular, periodic basis upon presentation by the Executive to the trustee of a statement or statements prepared by such counsel in accordance with its customary practices. Any failure by the Company to satisfy any of its
obligations under this Section 7(b) shall not limit the rights of the Executive hereunder. Subject to the foregoing, the Executive shall have the status of a general unsecured creditor of the Company and shall have no right to, or security
interest in, any assets of the Company or any Subsidiary. 
 (c) The reimbursement obligations of the Company under
Section 7(a) and Section 7(b) shall be paid no later than December 31 of the calendar year following the calendar year in which the related expense is incurred; provided that in no event shall the reimbursement provided by the Company
in one taxable year affect the amount of reimbursement provided in any other taxable year nor shall Executive’s right to reimbursement be subject to liquidation or exchange for another benefit. 

8. Competitive Activity; Confidentiality; Nonsolicitation. (a) For a period ending one year following the Termination Date,
if the Executive shall have received or shall be receiving benefits under Section 4, the Executive shall not, without the prior written consent of the Company, which consent shall not be unreasonably withheld, engage in any Competitive
Activity; provided that the foregoing shall not apply if the Termination Date was prior to the Change in Control and Executive had already commenced such activity. 
 (b) During the Term, the Company agrees that it will disclose to Executive its confidential or proprietary information (as defined in this Section 8(b)) to the extent necessary for Executive to carry
out his obligations to the Company. The Executive hereby covenants and 

  
 9 

 
agrees that he will not, without the prior written consent of the Company, during the Term or thereafter disclose to any person not employed by the Company, or use in connection with engaging in
competition with the Company, any confidential or proprietary information of the Company. For purposes of this Agreement, the term “confidential or proprietary information” will include all information of any nature and in any form that is
owned by the Company and that is not publicly available (other than by Executive’s breach of this Section 8(b)) or generally known to persons engaged in businesses similar or related to those of the Company. Confidential or proprietary
information will include, without limitation, the Company’s financial matters, customers, employees, industry contracts, strategic business plans, product development (or other proprietary product data), marketing plans, and all other secrets
and all other information of a confidential or proprietary nature. For purposes of the preceding two sentences, the term “Company” will also include any Subsidiary (collectively, the “Restricted Group”). The foregoing
obligations imposed by this Section 8(b) will not apply (i) during the Term, in the course of the business of and for the benefit of the Company, (ii) if such confidential or proprietary information will have become, through no fault
of the Executive, generally known to the public or (iii) if the Executive is required by law to make disclosure (after giving the Company notice and, to the extent feasible, an opportunity to contest such requirement). 

(c) The Executive hereby covenants and agrees that during the Term and for one year thereafter Executive will not, without the prior
written consent of the Company, which consent shall not unreasonably be withheld, on behalf of Executive or on behalf of any person, firm or company, directly or indirectly, attempt to influence, persuade or induce, or assist any other person in so
persuading or inducing, any management employee of the Restricted Group to give up employment with the Restricted Group, provided the foregoing shall not be violated by advertising or searches not specifically targeted at the management employees of
the Restricted Group, or serving as a reference. 
 (d) Executive and the Company agree that the covenants contained in this
Section 8 are reasonable under the circumstances, and further agree that if in the opinion of any court of competent jurisdiction any such covenant is not reasonable in any respect, such court will have the right, power and authority to excise
or modify any provision or provisions of such covenants as to the court will appear not reasonable and to enforce the remainder of the covenants as so amended. Executive acknowledges and agrees that the remedy at law available to the Company for
breach of any of his obligations under this Section 8 would be inadequate and that damages flowing from such a breach may not readily be susceptible to being measured in monetary terms. Accordingly, Executive acknowledges, consents and agrees
that, in addition to any other rights or remedies that the Company may have at law, in equity or under this Agreement, upon adequate proof of his violation of any such provision of this Agreement, the Company will be entitled to immediate injunctive
relief and may obtain a temporary order restraining any threatened or further breach, without the necessity of proof of actual damage. 
 9. Employment Rights. Nothing expressed or implied in this Agreement will create any right or duty on the part of the Company or the Executive to have the Executive remain in the employment of the
Company or any Subsidiary prior to or following any Change in Control. 

  
 10 

 10. Withholding of Taxes. The Company may withhold from any amounts payable under
this Agreement all federal, state, city or other taxes as the Company is required to withhold pursuant to any applicable law, regulation or ruling. 
 11. Successors and Binding Agreement. 
 (a) The Company will require any
successor (whether direct or indirect, by purchase, merger, consolidation, reorganization or otherwise) to all or substantially all of the business or assets of the Company, by agreement in form and substance reasonably satisfactory to the
Executive, expressly to assume and agree to perform this Agreement in the same manner and to the same extent the Company would be required to perform if no such succession had taken place. This Agreement will be binding upon and inure to the benefit
of the Company and any successor to the Company, including without limitation any persons acquiring directly or indirectly all or substantially all of the business or assets of the Company whether by purchase, merger, consolidation, reorganization
or otherwise (and such successor shall thereafter be deemed the “Company” for the purposes of this Agreement), but will not otherwise be assignable, transferable or delegable by the Company. 

(b) This Agreement will inure to the benefit of and be enforceable by the Executive’s personal or legal representatives, executors,
administrators, successors, heirs, distributees and legatees. 
 (c) This Agreement is personal in nature and neither of the
parties hereto shall, without the consent of the other, assign, transfer or delegate this Agreement or any rights or obligations hereunder except as expressly provided in Sections 11(a) and 11(b). Without limiting the generality or effect of
the foregoing, the Executive’s right to receive payments hereunder will not be assignable, transferable or delegable, whether by pledge, creation of a security interest, or otherwise, other than by a transfer by Executive’s will or by the
laws of descent and distribution and, in the event of any attempted assignment or transfer contrary to this Section 11(c), the Company shall have no liability to pay any amount so attempted to be assigned, transferred or delegated. 

12. Notices. For all purposes of this Agreement, all communications, including without limitation notices, consents, requests or
approvals, required or permitted to be given hereunder will be in writing and will be deemed to have been duly given when hand delivered or dispatched by electronic facsimile transmission (with receipt thereof orally confirmed), or five business
days after having been mailed by United States registered or certified mail, return receipt requested, postage prepaid, or three business days after having been sent by a nationally recognized overnight courier service such as FedEx, UPS, or
Purolator, addressed to the Company (to the attention of the Secretary of the Company) at its principal executive office and to the Executive at his address on the books of the Company, or to such other address as any party may have furnished to the
other in writing and in accordance herewith, except that notices of changes of address shall be effective only upon receipt. 

13. Governing Law. The validity, interpretation, construction and performance of this Agreement will be governed by and construed
in accordance with the substantive laws of the State of Delaware, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction.

  
 11 

 14. Consent to Jurisdiction. Any disputes, litigation, proceedings or other legal
actions by any party to this Agreement in connection with or relating to this Agreement or any matters described or contemplated in this Agreement may be instituted in the courts of the State of Delaware or of the United States sitting in the State
of Delaware. Each party to this Agreement irrevocably submits to the jurisdiction of the courts of the State of Delaware and of the United States sitting in the State of Delaware in connection with any such dispute, litigation, proceeding or other
legal action arising out of or relating to this Agreement. 
 15. Validity. If any provision of this Agreement or the
application of any provision hereof to any person or circumstance is held invalid, unenforceable or otherwise illegal, the remainder of this Agreement and the application of such provision to any other person or circumstance will not be affected,
and the provision so held to be invalid, unenforceable or otherwise illegal will be reformed to the extent (and only to the extent) necessary to make it enforceable, valid or legal. 

16. Miscellaneous. No provision of this Agreement may be modified, waived or discharged unless such waiver, modification or
discharge is agreed to in writing signed by the Executive and the Company. No waiver by either party to this Agreement at any time of any breach by the other contracting party or compliance with any condition or provision of this Agreement to be
performed by such other party will be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time. No agreements or representations, oral or otherwise, expressed or implied with respect to the
subject matter hereof have been made by either party which are not set forth expressly in this Agreement. References to Sections are to references to Sections of this Agreement. 

17. Code Section 409A. The intent of the parties hereto is that payments and benefits under this Agreement comply with or be
exempt from Code Section 409A and the regulations and guidance promulgated thereunder (collectively “Section 409A”) and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted and administered to
be in compliance therewith. To the extent that there is a material risk that any payments under this Agreement may result in the imposition of an additional tax to the Executive under Section 409A, the Company will reasonably cooperate with the
Executive to amend this Agreement such that payments hereunder comply with Section 409A without materially changing the economic value of this Agreement to either party. The Company shall use its best efforts to ensure ongoing compliance with
Section 409A. Notwithstanding any provision in this Agreement to the contrary, no payment or benefit that is deferred compensation for purposes of Section 409A and that is due upon the Executive’s termination of employment will be
paid or provided unless such termination is also a separation from service (within the meaning of Section 409A). For purposes of Section 409A, the Executive’s right to receive any installment payments pursuant to this Agreement shall
be treated as a right to receive a series of separate and distinct payments. Whenever a payment under this Agreement specifies a payment period with reference to a number of days (e.g., “payment shall be made within 30 days following the
date of termination”), the actual date of payment within the specified period shall be within the sole discretion of the Company. 

  
 12 

 18. Section 409A Delay. If the Executive is at the time of the Executive’s
separation from service (as defined in Section 409A) with the Company (other than as a result of the Executive’s death) a “Specified Employee,” as such term is defined under Section 409A and using the identification
methodology selected by the Company from time to time, then with regard to any payment or the provision of any benefit that is considered deferred compensation under Section 409A and that is payable on account of a separation from service shall
be delayed until the earlier of the Executive’s death or six months after the Executive’s separation from service (the “Section 409A Delay”) and shall then be promptly paid to the Executive in a lump sum, together
with interest for the period of delay, compounded annually, equal to the prime rate (as published in The Wall Street Journal) and in effect as of the date the payment should otherwise have been provided, and any remaining payments and
benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein. 
 19. Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same agreement.

  
 13 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered
as of the date first above written. 
  

			
	“Company”
	
	 HARMAN INTERNATIONAL

INDUSTRIES, INCORPORATED

		
	By:	 	  

	Name:	 	  

	Its:	 	  

	
	“Executive”
	
	  

	  

  
 14 

 Annex A 
 Severance Compensation 
 (1) A lump sum payment in an amount equal to 1.5
times the Base Pay (at the highest rate in effect for any period prior to the Termination Date). 
 (2) Outplacement services
for one year after the Termination Date by a firm selected by the Executive, at the expense of the Company in an amount up to $50,000. 

  
 A-1Employment Agreement between Raptor and Georgia Erbez

 Exhibit 10.1 
 [*****] Raptor Pharmaceutical Corp. has requested confidential treatment of certain portions of this agreement which have been omitted and filed separately with the U.S. Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934. 
  

 EMPLOYMENT AGREEMENT 

This Employment Agreement (this “Agreement”) is entered into as of this 10th day of September, 2012 (the
“Effective Date”) by and between Raptor Pharmaceutical Corp., a Delaware corporation with its principal offices located at 9 Commercial Blvd., Suite 200, Novato, California 94949 (the “Company”), and
Georgia Erbez, a resident of Contra Costa County, California (“Employee”). 
 WHEREAS, the Company and
Employee desire and agree to enter into an employer/employee relationship, subject to the terms and conditions as provided below. 
 NOW THEREFORE, in consideration of the foregoing and for other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby enter into this Agreement as
follows: 
 1. Position. During the term of this Agreement, the Company will employ Employee, and Employee will
serve the Company in the capacity of Chief Financial Officer. Employee will report directly to the Chief Executive Officer (the “CEO”) of the Company. 
 2. Duties. Employee will perform duties that are executive in nature, consistent with her title and initially shall be responsible for effectively directing the Company’s Global
Financial Strategy and Organization and providing effective leadership in defining, communicating, and executing corporate and financial strategic initiatives. Employee will lead the development and execution of the Investor Relations program of the
Company, including, without limitation, directing strategic communications, providing a primary point of contact for investors and analysts, and leading the annual shareholder meeting as well as investor conferences. Employee will also provide
oversight of and strategic direction to the Company’s global human resources programs. Employee shall have such other duties as may be assigned to her by the CEO from time to time as are consistent with Employee’s position, and at the
CEO’s request, shall perform services for the Company’s affiliates. 
 3. Exclusive Service. Employee
will devote substantially all her working time and efforts to the business and affairs of the Company. The foregoing shall not, however, preclude Employee from (a) engaging in appropriate civic, charitable or religious activities,
(b) devoting a reasonable amount of time to private investments and business interests, or (c) providing incidental assistance to family members on matters of family business, so long as the foregoing activities and service do not conflict
with Employee’s responsibilities to the Company. Employee shall only serve on the boards of directors or advisors of, or as a consultant to, other entities if (i) the Board of Directors of the Company (the “Board of
Directors”) has approved such service in advance in writing and (ii) such service does not conflict with Employee’s responsibilities. 

 [*****] Raptor Pharmaceutical Corp. has requested confidential treatment of certain portions of
this agreement which have been omitted and filed separately with the U.S. Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934. 

 

 4. Term of Employment. 

4.1 Initial Term. The Company agrees to continue Employee’s employment, and Employee agrees to remain in the employ of
the Company, for a period of three (3) years after the Effective Date unless Employee’s employment is earlier terminated pursuant to the provisions of this Agreement. 

4.2 Renewal. The term of Employee’s employment shall be extended automatically, without further action of either
party, as of ninety (90) days prior to the third anniversary of the Effective Date and on each succeeding anniversary of that date, for terms of one (1) year, unless on or before ninety (90) days prior to the last day of the term of
Employee’s employment or any extension thereof, the Company or Employee shall notify the other in writing of its intention not to renew Employee’s employment. Any such renewal shall be upon such terms and conditions set forth herein,
unless otherwise agreed in writing between the Company and Employee. The notice of non-renewal by either party shall in no way constitute a breach of this Agreement. 
 4.3 Termination of Agreement. This Agreement shall terminate on the date on which all obligations of the parties hereto have been satisfied. 

5. Compensation and Benefits. 
 5.1 Base Salary. For each full year during the term of Employee’s employment with the Company, the Company agrees to pay Employee a minimum annual salary of three hundred thirty
thousand dollars ($330,000) (the “Base Salary”). In the event of any portion of a year, the Company shall pay Employee a pro rata amount of such Base Salary. Employee’s Base Salary shall be reviewed by the Board of
Directors including for possible increases in accordance with the Company’s compensation review practices. Increases, if any, shall be effective at the beginning of the fiscal year in which the Board of Directors conducts such review.
Employee’s Base Salary will be payable as earned in accordance with the Company’s customary payroll practice. 

5.2 Cash Bonus. Employee will be eligible to receive annual and discretionary cash bonuses as determined by the Board of
Directors; provided, however, that with respect to any such bonus, Employee must be employed on the date any such bonus actually is paid in order to be eligible to receive such bonus. The annual discretionary bonus (“Annual
Bonus”) shall have a target payment of 40% of Employee’s Base Salary for the year in question. The Board of Directors shall decide whether to award an Annual Bonus and, if so, the amount thereof, after consideration of the extent
to which Employee achieved her annual objectives for the year in question (“Annual Objectives”). Employee’s Annual Objectives shall be jointly agreed upon between Employee and the CEO as shall any modifications thereto,
but such Annual Objectives and any modifications thereto shall be subject to approval by the Compensation Committee of the Board of Directors and the Board of Directors. 

 [*****] Raptor Pharmaceutical Corp. has requested confidential treatment of certain portions of
this agreement which have been omitted and filed separately with the U.S. Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934. 

 

 5.3 Additional Benefits. Employee will be eligible to participate in the
employee benefit plans of the Company and its affiliates of general application in accordance with the rules established for individual participation in any such plan. Employee shall be entitled each year to four (4) weeks leave for vacation at
full pay, provided, that the maximum amount Employee may have accrued at any point in time is four (4) weeks (meaning that once Employee has accrued four (4) weeks, Employee will not accrue any additional vacation time until she
takes vacation and falls below the four (4) weeks accrual cap). Employee shall also be entitled to reasonable holidays and illness days with full pay in accordance with the policies applicable to the Company and its affiliates (the
“Policies”) from time to time in effect. Employee acknowledges and agrees that in order to maintain flexibility, the Company and its affiliates have the right to amend or terminate any employee benefit plan at any time.

 5.4 Stock Options. Subject to approval by the Board of Directors, Employee will be granted
options to purchase 190,000 shares of Raptor’s common stock at the closing price on the day preceding the date of grant. Subject to Employee’s continued employment with the Company through each applicable vesting date, such stock options
will vest 6/48ths on the six month anniversary of the grant date and 1/48th per month on each subsequent monthly anniversary of the grant date and will expire ten (10) years from date of grant. Employee will be eligible to receive future stock grants and stock option
awards at the discretion of the Board of Directors. Notwithstanding anything to the contrary contained in this Agreement, such options shall be subject to the terms and conditions of the Raptor 2010 Stock Incentive Plan, as amended from time to
time, and the applicable Notice of Grant and Stock Option Agreement. 
 5.5 Expenses. The Company will reimburse
Employee for all reasonable and necessary expenses incurred by Employee in connection with the Company’s business, provided that such expenses are in accordance with applicable Policies set by the Board of Directors from time to time and are
properly documented and accounted for in accordance with such Policies and with the requirements of the Internal Revenue Service. 
 6. Proprietary Rights. Employee hereby agrees to execute an Employee Invention Assignment and Confidentiality Agreement with the Company in substantially the form attached hereto as
Exhibit A and understands and agrees that her employment is contingent on her doing so. 

 [*****] Raptor Pharmaceutical Corp. has requested confidential treatment of certain portions of
this agreement which have been omitted and filed separately with the U.S. Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934. 

 

 7. Termination. 

7.1 Events of Termination. Employee’s employment with the Company shall terminate upon any one of the following:

 (a) Ninety (90) days after the effective date of a written notice sent to Employee stating the Company’s
determination made in good faith that it is terminating Employee for “Cause” as defined under Section 7.2 below (“Termination for Cause”), provided, that if the “Cause” for termination is a
curable failure by Employee to properly perform her assigned duties, then the Company will give Employee written notice of such failure (a “Cause Notice”), and if Employee fails to cure such failure to the reasonable
satisfaction of the Board of Directors within sixty (60) days after the Company gives the Cause Notice, then the Company may immediately terminate Employee’s employment, and such termination will be conclusively deemed to be for
“Cause” hereunder; or 
 (b) Fourteen (14) days after the effective date of a written notice sent to Employee
stating the Company’s determination made in good faith that, due to a mental or physical incapacity, Employee has been unable to perform her duties under this Agreement for a period of not less than six (6) consecutive months or 180 days
in the aggregate in any 12-month period (“Termination for Disability”); or 
 (c)
Employee’s death (“Termination Upon Death”); or 
 (d) The effective date of a written notice sent
to the Company stating Employee’s determination made in good faith of “Constructive Termination” by the Company, as defined under Section 7.3 below (“Constructive Termination”); or 

(e) Fourteen (14) days after the effective date of a notice sent to Employee stating that the Company is terminating her
employment, without Cause, which notice can be given by the Company at any time after the Effective Date at the Company’s sole discretion, for any reason or for no reason (“Termination Without Cause”); or

 (f) The effective date of a notice sent to the Company from Employee stating that Employee is electing to terminate her
employment with the Company (“Voluntary Termination”). 
 7.2 “Cause” Defined.
For purposes of this Agreement, “Cause” for Employee’s termination means: 
 (a) Employee’s commission of a
felony or other crime involving moral turpitude; or 
 (b) any willful act or acts of dishonesty undertaken by Employee and
intended to result in substantial gain or personal enrichment of Employee, Employee’s family or any third party at the expense of the Company; or 
 (c) any willful act of gross misconduct which is materially and demonstrably injurious to the Company; or 

 [*****] Raptor Pharmaceutical Corp. has requested confidential treatment of certain portions of
this agreement which have been omitted and filed separately with the U.S. Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934. 

 

 (d) Employee’s inability to lawfully work in the United States. 

No act, or failure to act, by Employee shall be considered “willful” if done, or omitted to be done, by her in good faith and
in the reasonable belief that her act or omission was in the best interest of the Company and/or required by applicable law. 

7.3 “Constructive Termination” Defined. “Constructive Termination” shall mean, the occurrence of one or
more of the following events without Employee’s consent, provided that Employee first gives the Company written notice of her intention to terminate and of the grounds for such termination within ninety (90) days of the initial occurrence
of such event, the Company has not cured such event within thirty (30) days of its receipt of such notice, and Employee actually terminates her employment for such reason within thirty (30) days of the Company’s failure to cure:

 (a) a material reduction in Employee’s Base Salary (other than as part of a reduction in the base salary of at least a
majority of the Company’s executives of the same or greater percentage); or 
 (b) a material diminution in
Employee’s responsibilities; or 
 (c) the Company’s material breach of any material term of this Agreement; or

 (d) a requirement that Employee relocate to an office that would increase Employee’s one-way commute distance by more
than fifty (50) miles based on Employee’s primary residence at the time such relocation is announced. 
 8.
Effect of Termination. In the event of any termination of Employee’s employment, the Company shall immediately pay to Employee or Employee’s estate, as applicable, the compensation and benefits otherwise payable to Employee
under Section 5 through the date of termination and shall have no further obligation to Employee under this Agreement, except as otherwise provided in this Section 8. 
 8.1 Termination for Cause or Voluntary Termination Or Any Termination on or After the Last Day of the Term of This Agreement. In the event of any termination of Employee’s employment
pursuant to Section 7.1(a) or Section 7.1(f), or any termination concurrent with or after the anniversary date of this agreement on which a notice of non-renewal is effective under Section 4.2, the Company shall immediately pay to
Employee the compensation and benefits otherwise payable to Employee under Section 5 through the date of termination. Employee’s rights under the Company’s benefit plans of general application shall be determined under the provisions
of those plans. The Company shall have no other obligation to Employee under this Agreement. 

 [*****] Raptor Pharmaceutical Corp. has requested confidential treatment of certain portions of
this agreement which have been omitted and filed separately with the U.S. Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934. 

 

 8.2 Termination for Disability. In the event of termination of employment
pursuant to Section 7.1(b), for three (3) months after the termination of Employee’s employment, (A) the Company shall continue to pay Employee her Base Salary under Section 5.1 above at Employee’s then-current Base
Salary, payable on the Company’s normal payroll dates during that period and (B) the Company shall reimburse or pay the cost of continuing the Company-sponsored (non-FSA) group health plan coverage under COBRA, provided that Employee
timely elects COBRA continuation coverage, but only to the extent that doing so will not result in unintended adverse tax consequences under Section 105(h) of the Internal Revenue Code, the Patient Protection and Affordable Care Act or other
similar applicable law. Notwithstanding the foregoing, Employee shall not receive any amounts or benefits described in this Section 8.2 unless Employee executes a general release in the form prescribed by the Company (which release may contain
such non-release terms and conditions as the Company deems appropriate) and such general release becomes effective and irrevocable by the 60th day following Employee’s termination of employment (the “General Release
Requirements”). In addition, no amount described in this Section 8.2 shall be payable prior to the 61st day following Employee’s termination of employment, but if Employee satisfies the General Release Requirements, Company
shall pay Employee any cash amounts that otherwise would have been paid under this Section 8.2 during such 60 day period in a lump sum on the 61st day following Employee’s termination of employment. 

8.3 Termination Upon Death. In the event of termination of employment pursuant to Section 7.1(c), the Company shall
immediately pay to Employee’s estate or family (at the Company’s election) an amount equal to three months of Employee’s Base Salary. 
 8.4 Constructive Termination or Termination without Cause other than in the 12 Months Following a Change in Control. In the event of any termination of this Agreement pursuant to
Section 7.1(d) or Section 7.1(e) that does not occur within the 12 months following a Change in Control and subject to Section 8.6: 
 (a) beginning on the next payroll date immediately following the termination of Employee’s employment, (A) the Company shall continue to pay Employee for twelve (12) months after such
termination, her salary under Section 5.1 above at Employee’s then-current Base Salary, payable on the Company’s normal payroll dates during that period and (B) the Company shall reimburse or pay the cost of continuing any the
Company-sponsored (non-FSA) group health plan coverage under COBRA for twelve (12) months or, if earlier, until the date on which Employee first is or becomes eligible to enroll in another group health plan providing for reasonably comparable
coverage the monthly cost of which is subsidized by at least 50%, provided that Employee timely elects and remains eligible for COBRA continuation coverage, but only to the extent that doing so will not result in unintended adverse tax consequences
under Section 105(h) of the Internal Revenue Code, the Patient Protection and Affordable Care Act or other similar applicable law, and 

 [*****] Raptor Pharmaceutical Corp. has requested confidential treatment of certain portions of
this agreement which have been omitted and filed separately with the U.S. Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934. 

 

 (b) all of Employee’s vested options or stock appreciation rights with respect to
the Company’s common stock shall remain exercisable until the first anniversary of Employee’s termination of employment (or, if earlier, the maximum period specified in the award documents and plans governing such options or stock
appreciation rights, as applicable, assuming Employee’s employment had not terminated), and all shares of the Company’s common stock owned by Employee shall immediately be released from any and all resale or repurchase rights restrictions
(other than those imposed under applicable law). Notwithstanding the foregoing, Employee shall not receive any amounts or benefits described in this Section 8.4 unless Employee timely satisfies the General Release Requirements. In addition, no
amount described in subsection (a) above shall be payable prior to the 61st day following Employee’s termination of employment, but if Employee timely satisfies the General Release Requirements, the Company shall pay Employee any cash
amounts that otherwise would have been paid under subsection (a) above during such 60 day period in a lump sum on the 61st day following Employee’s termination of employment. 

8.5 Constructive Termination or Termination Without Cause In The 12 Months Following A Change In Control. In the event of
any termination of this Agreement pursuant to Section 7.1(d) or Section 7.1(e) that occurs within the 12 months following a Change in Control, in lieu of the benefits provided under Section 8.4 and subject to Section 8.6:

 (a) beginning on the next payroll date immediately following the termination of Employee’s employment, (i) the
Company shall continue to pay Employee for twelve (12) months after such termination, her salary under Section 5.1 above at Employee’s then-current Base Salary, payable on the Company’s normal payroll dates during that period and
(ii) the Company shall reimburse or pay the cost of continuing any the Company-sponsored (non-FSA) group health plan coverage under COBRA for twelve (12) months, or if earlier, until the date on which Employee first is or becomes eligible
to enroll in another group health plan providing for reasonably comparable coverage the monthly cost of which is subsidized by at least 50%, provided that Employee timely elects and remains eligible for COBRA continuation coverage, but only to the
extent that doing so will not result in unintended adverse tax consequences under Section 105(h) of the Internal Revenue Code, the Patient Protection and Affordable Care Act or other similar applicable law, and 

 [*****] Raptor Pharmaceutical Corp. has requested confidential treatment of certain portions of
this agreement which have been omitted and filed separately with the U.S. Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934. 

 

 (b) all of Employee’s unvested options, restricted stock units, stock awards,
stock appreciation rights, restricted stock and similar equity awards (collectively, “Equity Compensation”), if any, which have been issued (i) by the Company to Employee that are unvested as of the date of the Change in
Control or (ii) by the acquiring company to replace any Equity Compensation granted by the Company to Employee will become immediately vested. Any Equity Compensation which become vested pursuant to the foregoing sentence shall (1) only be
exercisable or delivered to Employee to the extent that Employee timely satisfies the General Release Requirements and (2) once exercisable, shall remain exercisable until the second anniversary of Employee’s termination of employment (or,
if earlier, the maximum period specified in the award or the plans governing such Equity Compensations if Employee’s employment had not terminated), and all shares of the Company’s common stock owned by Employee shall immediately be
released from any and all resale or repurchase restrictions (other than those imposed under applicable law). 
 (c) the Company
shall pay Employee a lump sum equal to the Adjusted Annual Cash Bonus (for purposes of this Section 8.5(c), the term “Adjusted Annual Cash Bonus” means the average Annual Bonus Employee received with respect to the two years preceding
the year of termination or, if two Annual Bonus payment dates have not occurred (regardless of whether Employee received an Annual Bonus on such dates) prior to Employee’s termination of employment, the Annual Bonus Employee received with
respect to the year preceding the year of termination or, if an Annual Bonus payment date has not occurred prior to Employee’s termination of employment, 40% of Employee’s Base Salary, which amount shall be paid on the 61st day following
Employee’s termination of employment, and in no event later than the end of the taxable year that includes such anniversary. 
 (d) For the purposes of this Agreement, the term “Change in Control” means the occurrence of any of the following events: (i) any sale or exchange of the capital stock by the stockholders
of the Company in one transaction or series of related transactions where more than fifty percent (50%) of the outstanding voting power of the Company is acquired by a person or entity or group of related persons or entities; or (ii) any
reorganization, consolidation or merger of the Company where the outstanding voting securities of the Company immediately before the transaction represent or are converted into less than fifty percent (50%) of the outstanding voting power of
the surviving entity (or its parent corporation) immediately after the transaction; or (iii) the consummation of any transaction or series of related transactions that results in the sale of all or substantially all of the assets of the
Company; or (iv) any “person” or “group” (as defined in the Securities Exchange Act of 1934, as amended (the “Exchange Act”) becoming the “beneficial owner” (as defined in Rule 13d-3 under
the Exchange Act) directly or indirectly of securities representing more than fifty percent (50%) of the voting power of the Company then outstanding. 

 [*****] Raptor Pharmaceutical Corp. has requested confidential treatment of certain portions of
this agreement which have been omitted and filed separately with the U.S. Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934. 

 

 (e) Notwithstanding the foregoing, Employee shall not receive any amounts or benefits
described in subsection (a) or (c) above unless Employee timely satisfies the General Release Requirements. In addition, no amount described in subsection (a) or (c) above shall be payable prior to the 61st day following
Employee’s termination of employment, but if Employee timely satisfies the General Release Requirements, the Company shall pay Employee any cash amounts that otherwise would have been paid under subsection (a) or (c) above during such
60 day period in a lump sum on the 61st day following Employee’s termination of employment. 
 8.6 Severance
Exclusion in Connection with certain Employment and Employment Offers in Connection with a Change In Control. Notwithstanding anything to the contrary contained in this Agreement, Employee will not be eligible for severance benefits under
Section 8.5 in connection with a Termination without Cause or a Constructive Termination occurring on or after a Change in Control if, no later than the date of such Change in Control, Employee is offered and accepts another position with the
Company, the surviving entity in a Change in Control, an entity that purchases all or substantially all of the Company’s assets in a Change in Control, any of the affiliates of the foregoing entities, or a Successor Employer. 

9. Miscellaneous. 
 9.1 Dispute Resolution. 
 (a) Arbitration of Disputes.
Any dispute under this Agreement shall be resolved by arbitration in the State of California, Marin County, and, except as herein specifically stated, in accordance with the National Rules for the Resolution of Employment Disputes of the
American Arbitration Association (“AAA Rules”) then in effect. However, in all events, these arbitration provisions shall govern over any conflicting rules which may now or hereafter be contained in the AAA
Rules. Any judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction over the subject matter thereof. The arbitrator shall have the authority to grant any equitable and legal remedies that would be available
in any judicial proceeding instituted to resolve such dispute; provided, however, that the parties retain their right to, and shall not be prohibited, limited or in any other way restricted from, seeking or obtaining equitable
relief from a court having jurisdiction over the parties. 
 (b) Selection of Arbitrator. The American
Arbitration Association will have the authority to select an arbitrator from a list of arbitrators who are partners in a nationally recognized firm of independent certified public accountants from the management advisory services department (or
comparable department or group) of such firm; provided, however, that such firm cannot be the firm of certified public accountants then auditing the books and records of either party or providing management or advisory services for either party.

 [*****] Raptor Pharmaceutical Corp. has requested confidential treatment of certain portions of
this agreement which have been omitted and filed separately with the U.S. Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934. 

 

 (c) Payment of Costs. Employee shall bear only those costs of arbitration
she would otherwise bear had she brought a claim covered by this Agreement in court. 
 (d) Burden of Proof. For
any dispute submitted to arbitration, the burden of proof will be as it would be if the claim were litigated in a judicial proceeding. 
 (e) Award. Upon the conclusion of any arbitration proceedings hereunder, the arbitrator will render findings of fact and conclusions of law and a written opinion setting forth the basis and
reasons for any decision reached and will deliver such documents to each party to this Agreement along with a signed copy of the award. 
 (f) Terms of Arbitration. The arbitrator chosen in accordance with these provisions will not have the power to alter, amend or otherwise affect the terms of these arbitration provisions or
the provisions of this Agreement. 
 (g) Exclusive Remedy. Except as specifically otherwise provided in this
Agreement, arbitration will be the sole and exclusive remedy of the parties for any dispute arising out of this Agreement. 

9.2 Severability. If any provision of this Agreement shall be found by any arbitrator or court of competent jurisdiction to
be invalid or unenforceable, then the parties hereby waive such provision to the extent that it is found to be invalid or unenforceable and to the extent that to do so would not deprive one of the parties of the substantial benefit of its bargain.
Such provision shall, to the extent allowable by law and the preceding sentence, be modified by such arbitrator or court so that it becomes enforceable and, as modified, shall be enforced as any other provision hereof, all the other provisions
continuing in full force and effect. 
 9.3 No Waiver. The failure by either party at any time to require
performance or compliance by the other of any of its obligations or agreements shall in no way affect the right to require such performance or compliance at any time thereafter. The waiver by either party of a breach of any provision hereof shall
not be taken or held to be a waiver of any preceding or succeeding breach of such provision or as a waiver of the provision itself. No waiver of any kind shall be effective or binding, unless it is in writing and is signed by the party against whom
such waiver is sought to be enforced. 
 9.4 Assignment. This Agreement and all rights hereunder are personal to
Employee and may not be transferred or assigned by Employee at any time. The Company may assign its rights, together with its obligations hereunder, to any parent, subsidiary, affiliate or successor, or in connection with any sale, transfer or other
disposition of all or substantially all of its business and assets, provided, however, that any such assignee assumes the Company’s obligations hereunder. 

 [*****] Raptor Pharmaceutical Corp. has requested confidential treatment of certain portions of
this agreement which have been omitted and filed separately with the U.S. Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934. 

 

 9.5 Withholding; Code Section 409A. All sums payable to Employee
hereunder shall be reduced by all federal, state, local and other withholding and similar taxes and payments required by applicable law. Notwithstanding anything in this Agreement to the contrary, if any amounts or benefits payable under this
Agreement in the event of Employee’s termination of employment constitute “nonqualified deferred compensation” within the meaning of Code Section 409A, payment of such amounts and benefits shall commence when Employee incurs a
“separation from service” within the meaning of Treasury Regulation 1.409A-1(h), without regard to any of the optional provisions thereunder, from the Company and any entity that would be considered a single employer with the Company under
Code Section 414(b) or 414(c) (“Separation from Service”). Such payments or benefits shall be provided in accordance with the timing provisions of this Agreement by substituting the Agreement’s references to
“termination of employment,” “termination” or similar concepts or phrases with Separation from Service. Notwithstanding the foregoing, if at the time of Employee’s Separation from Service Employee is a “specified
employee” within the meaning of Code Section 409A(a)(2)(B)(i), any amount or benefits that constitute “nonqualified deferred compensation” within the meaning of Code Section 409A that become payable to Employee on account of
Employee’s Separation from Service will not be paid until after the earlier of (i) first business day of the seventh month following Employee’s Separation from Service, or (ii) the date of Employee’s death (the
“409A Suspension Period”). Within 14 calendar days after the end of the 409A Suspension Period, Employee shall be paid a cash lump sum payment equal to any payments (without interest) and benefits that the Company would
otherwise have been required to provide under this Agreement but for the imposition of the 409A Suspension Period. Thereafter, Employee shall receive any remaining payments and benefits due under this Agreement in accordance with the terms of this
Section (as if there had not been any Suspension Period beforehand). For the purposes of this Agreement, each payment that is part of a series of installment payments shall be treated as a separate payment for purposes of Code Section 409A. Any
reimbursement to Employee for expenses under this Agreement shall in all events be paid to her on or before the last day of Employee’s taxable year following the taxable year in which the expense was incurred. The payment or reimbursement of
expenses pursuant to this Section in one taxable year of Employee shall not affect the amount of the payment or reimbursement in any other taxable year. The right to payment or reimbursement under any section of this Agreement providing for
reimbursement of expenses shall not be liquidated or exchanged for any other benefit. 
 9.6 Entire Agreement.
This Agreement constitutes the entire and only agreement and understanding between the parties relating to employment of Employee with the Company and this Agreement supersedes and cancels any and all previous contracts, arrangements or
understandings, including without limitation, any and all oral contracts, arrangements or understandings, with respect to Employee’s employment; except that Employee Invention Assignment and Confidentiality Agreement shall remain
as an independent contract and shall remain in full force and effect according to its terms. 

 [*****] Raptor Pharmaceutical Corp. has requested confidential treatment of certain portions of
this agreement which have been omitted and filed separately with the U.S. Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934. 

 

 9.7 Amendment; Compliance with Section 409A. 

(a) This Agreement may be amended, modified, superseded, cancelled, renewed or extended only by an agreement in writing executed by both
parties hereto. 
 (b) This Agreement is intended to comply with (or be exempt from) Code Section 409(A), and the Company
shall have complete discretion to interpret, modify, amend or construe this Agreement and any associated documents in any manner that establishes compliance with (or an exemption from) the requirements of Section 409A of the Code. If, for any
reason including imprecision in drafting, the Agreement does not accurately reflect its intended establishment of compliance with (or an exemption from) Code Section 409A, as demonstrated by consistent interpretations or other evidence of
intent, the provision shall be considered ambiguous and shall be interpreted by the Company in a fashion consistent herewith, as determined in the sole and absolute discretion of the Company. Nevertheless, and notwithstanding any other provision of
this Agreement, neither the Company nor any of its employees, directors, or their agents shall have any obligation to mitigate, nor to hold Employee harmless from, any or all taxes (including any imposed under Code Section 409A) arising under
this Agreement. 
 9.8 At-will Employment. The employment relationship is “at-will,” meaning that
either party can terminate the relationship with or without cause with the consequences described herein. 
 9.9
Notices. All notices and other communications required or permitted under this Agreement shall be in writing and hand delivered, sent by telecopier, sent by registered first class mail, postage pre-paid, or sent by nationally recognized
express courier service. Such notices and other communications shall be effective upon receipt if hand delivered or sent by telecopier, five (5) days after mailing if sent by mail, and one (1) day after dispatch if sent by express courier,
to the following addresses, or such other addresses as any party shall notify the other parties: 
  

	 If to the Company: 
	Raptor Pharmaceutical Corp. 

	 	9 Commercial Blvd., Suite 200 

	 	Novato, CA 94949 

  

	 Telecopier: 
	415-382-1458 

  

	 Attention: 
	Chief Executive Officer 

  

	 If to Employee: 
	Georgia Erbez 

	 	[*****] 

  

	 Telecopier: 
	[•] 

 [*****] Raptor Pharmaceutical Corp. has requested confidential treatment of certain portions of
this agreement which have been omitted and filed separately with the U.S. Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934. 

 

 9.10 Binding Nature. This Agreement shall be binding upon, and inure to
the benefit of, the successors and personal representatives of the respective parties hereto. 
 9.11 Headings.
The headings contained in this Agreement are for reference purposes only and shall in no way affect the meaning or interpretation of this Agreement. In this Agreement, the singular includes the plural, the plural included the singular, the masculine
gender includes both male and female referents and the word “or” is used in the inclusive sense. 
 9.12
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original but all of which, taken together, constitute one and the same agreement. 

9.13 Governing Law. This Agreement and the rights and obligations of the parties hereto shall be construed in accordance
with the laws of the State of California, without giving effect to the principles of conflict of laws. 
 9.14
Attorneys’ Fees. In the event of any litigation or arbitration arising out of or with respect to this Agreement, the prevailing party shall be entitled to reasonable costs and attorneys’ fees, including any such costs and fees
upon appeal. 

 [*****] Raptor Pharmaceutical Corp. has requested confidential treatment of certain portions of
this agreement which have been omitted and filed separately with the U.S. Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934. 

 

 IN WITNESS WHEREOF, the Company and Employee have executed this Agreement as of the date
first above written. 
  

							
	Raptor Pharmaceutical Corp.	 		 	Georgia Erbez
			
	/s/    Christopher Starr	 		 	/s/    Georgia Erbez
	By:	 	Christopher Starr	 		 	
	Its:	 	Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}]]